Show simple item record

dc.contributor.authorOssa Gomez, Carlos Andrespt_BR
dc.contributor.authorAchatz, Maria Isabel Alves de Souza Waddingtonpt_BR
dc.contributor.authorHurtado Martínez, Mabel Andreapt_BR
dc.contributor.authorSanabria Salas, Maria Carolinapt_BR
dc.contributor.authorSullcahuaman Allende, Yasser Ciropt_BR
dc.contributor.authorChavarri Guerra, Yaninpt_BR
dc.contributor.authorDutilh, Juliept_BR
dc.contributor.authorNielsen, Sarah M.pt_BR
dc.contributor.authorEsplin, Edwardpt_BR
dc.contributor.authorMichalski, Scottpt_BR
dc.contributor.authorBristow, Sarapt_BR
dc.contributor.authorHatchell, Kathrynpt_BR
dc.contributor.authorNussbaum, Robert L.pt_BR
dc.contributor.authorPineda Alvarez, Daniel E.pt_BR
dc.contributor.authorProlla, Patrícia Ashtonpt_BR
dc.date.accessioned2024-03-28T06:24:40Zpt_BR
dc.date.issued2022pt_BR
dc.identifier.issn2687-8941pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/274338pt_BR
dc.description.abstractPURPOSE: To report on pathogenic germline variants detected among individuals undergoing genetic testing for hereditary breast and/or ovarian cancer (HBOC) from Latin America and compare them with self-reported Hispanic individuals from the United States. METHODS: In this cross-sectional study, unrelated individuals with a personal/family history suggestive of HBOC who received clinician-ordered germline multigene sequencing were grouped according to the location of the ordering physician: group A, Mexico, Central America, and the Caribbean; group B, South America; and group C, United States with individuals who self-reported Hispanic ethnicity. Relatives who underwent cascade testing were analyzed separately. RESULTS: Among 24,075 unrelated probands across all regions, most were female (94.9%) and reported a personal history suggestive of HBOC (range, 65.0%-80.6%); the mean age at testing was 49.1 6 13.1 years. The average number of genes analyzed per patient was highest in group A (A 63 6 28, B 56 6 29, and C 40 6 28). Between 9.1% and 18.7% of patients had pathogenic germline variants in HBOC genes (highest yield in group A), with the majority associated with high HBOC risk. Compared with US Hispanics individuals the overall yield was significantly higher in both Latin American regions (A v C P = 1.64×10–9 , B v C P , 2.2×10–16). Rates of variants of uncertain significance were similar across all three regions (33.7%-42.6%). Cascade testing uptake was low in all regions (A 6.6%, B 4.5%, and C 1.9%). CONCLUSION: This study highlights the importance of multigene panel testing in Latin American individuals with newly diagnosed or history of HBOC, who can benefit from medical management changes including targeted therapies, eligibility to clinical trials, risk-reducing surgeries, surveillance and prevention of secondary ma lignancy, and genetic counseling and subsequent cascade testing of at-risk relatives.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofJCO Global Oncology. United States. Vol. 8 (July 2022), e2200104, 13 p.pt_BR
dc.rightsOpen Accessen
dc.subjectVariação genéticapt_BR
dc.subjectHBOC-risk genesen
dc.subjectTestes genéticospt_BR
dc.titleGermline pathogenic variant prevalence among Latin American and us Hispanic individuals undergoing testing for hereditary breast and ovarian cancer: a cross-sectional studypt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001163202pt_BR
dc.type.originEstrangeiropt_BR


Files in this item

Thumbnail
   

This item is licensed under a Creative Commons License

Show simple item record